Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Work In Process (2024 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Work In Process for 2 consecutive years, with $4.3 million as the latest value for Q4 2025.

  • For Q4 2025, Work In Process rose 77.0% year-over-year to $4.3 million; the TTM value through Dec 2025 reached $4.3 million, up 77.0%, while the annual FY2025 figure was $4.3 million, 77.0% up from the prior year.
  • Work In Process was $4.3 million for Q4 2025 at Day One Biopharmaceuticals, down from $6.0 million in the prior quarter.
  • The five-year high for Work In Process was $6.0 million in Q3 2025, with the low at $2.4 million in Q4 2024.